Egalet
Lejrvej 37-41
Værløse
DK-3500
Tel: 45-44-47-80-80
Fax: 45-44-47-24-25
Website: http://www.egalet.com/
Email: info@egalet.com
167 articles about Egalet
-
Egalet Reports First Quarter 2019 Financial Results and Plan to Change Company Name to Zyla Life Sciences
5/16/2019
Egalet Corporation reported financial results for the first quarter ended March 31, 2019 and announced it will change its name to Zyla Life Sciences in the coming weeks.
-
Egalet to Host Conference Call and Webcast to Discuss First Quarter 2019 Financial Results on May 16, 2019
5/14/2019
Egalet Corporation announced that its first quarter 2019 financial results will be released on Thursday, May 16, 2019.
-
Adare Acquires Egalet’s Proprietary “ParvuletTM” Technology Platform
4/15/2019
Adare Pharmaceuticals, Inc. announced that it has entered into an agreement with Egalet Corporation, to acquire global rights of the “ParvuletTM” technology platform and its associated Intellectual Property.
-
Egalet Reports Third Quarter 2018 Financial Results
11/19/2018
-- Highest quarterly revenue for SPRIX Nasal Spray and OXAYDO --
-
Egalet Signs Asset Purchase Agreement to Acquire Four FDA-Approved, Non-Narcotic Pain Products
10/31/2018
Anticipates projected pro forma annual net revenue of between $80 and $90 million.
-
Egalet Reports Second Quarter 2018 Financial Results
8/8/2018
Improvements in formulary status for key products
-
Egalet to Host Conference Call and Webcast to Discuss Second Quarter 2018 Financial Results on August 8, 2018
7/25/2018
Egalet Corporation announced that its second quarter 2018 financial results will be released on Wednesday, August 8, 2018.
-
Egalet Appoints Industry Veteran John Varian to Board of Directors
6/7/2018
Varian most recently served as the CEO and director of XOMA, an antibody business, where he led the refocusing and refinancing of the company
-
Egalet to Participate in Panels at 2018 BIO International Convention and JMP Life Sciences Conference
6/4/2018
Egalet Corporation announced Bob Radie, president and chief executive officer, will present in panels at two upcoming conferences in June.
-
Egalet Announces Large Regional Plan to Cover SPRIX® Nasal Spray
5/29/2018
Egalet Corporation announced that a large Southeast regional health plan has placed SPRIX (ketorolac tromethamine) Nasal Spray in a tier 3 covered position effective immediately.
-
Egalet Presented Data at American Academy of Pain Medicine Examining the Potential of ARYMO® ER to Deter Opioid Abuse
4/30/2018
Egalet Corporation announced data on ARYMO ER (morphine sulfate) extended-release (ER) tablets CII were presented in four poster presentations at the 34th Annual Meeting of the American Academy of Pain Medicine (AAPM) in Vancouver, Canada.
-
Egalet to Host Conference Call and Webcast to Discuss First Quarter 2018 Financial Results on May 8, 2018
4/24/2018
Egalet Corporation announced that its first quarter 2018 financial results will be released on Tuesday, May 8, 2018.
-
Egalet to Present at Upcoming Conferences
3/21/2018
Egalet Corporation announced that members of the Egalet clinical and development teams will be presenting at two upcoming conferences.
-
Egalet Reports Fourth Quarter and Full Year 2017 Financial Results
3/12/2018
Egalet Corporation reported financial results for the fourth quarter and year ended December 31, 2017.
-
Egalet Announces a Large Regional Health Plan Placed ARYMO® ER and SPRIX® Nasal Spray in Preferred Formulary Positions
2/28/2018
"Obtaining preferred coverage of both ARYMO ER and SPRIX Nasal Spray is important to ensure access to our products for healthcare providers and for the individuals covered by this large health plan," said Patrick Shea, chief commercial officer of Egalet.
-
Egalet Announces ARYMO ER Data Published in Current Medical Research and Opinion Journal
1/29/2018
ARYMO ER is approved for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
-
Egalet's Partner OraPharma Begins Promotion of SPRIX Nasal Spray
1/23/2018
Egalet announced today that its partner OraPharma has begun promoting SPRIX Nasal Spray to more than 9,000 dentists and oral surgeons across the United States.
-
Egalet Partners With OraPharma to Co-Promote SPRIX Nasal Spray
1/3/2018
SPRIX Nasal Spray is a NSAID indicated for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level.
-
Egalet Reduces Debt Obligation, Extends Maturity and Lowers Annual Interest Payments through Refinancing of Existing Convertible Notes
12/20/2017
The exchange is expected to close on Friday, December 22, 2017, subject to customary closing conditions.
-
Egalet Receives FDA Tentative Approval for Expanded Label for ARYMO ER (morphine sulfate) C-II, an Extended-Release Morphine Product Formulated With Abuse-Deterrent Properties for Treatment of Chronic Pain
12/15/2017
The FDA has issued tentative approval for a supplement submitted earlier in 2017 to update the ARYMO ER prescribing information with data from a Category 2/3 intranasal HAP study and an intranasal abuse-deterrent claim.